A phase I study evaluates the combination of the CDK4/6 inhibitor abemaciclib with anti-PD-1 antibody pembrolizumab for KRAS mutant, PD-L1+ patients with stage IV NSCLC (NCT02779751). This evidence concerns the gene KRAS and non-small cell lung carcinoma.